Literature DB >> 19377363

Previous Out-of-Pocket Drug Expenditures and Patterns of Antidepressant Use among Workers Receiving Depression-Related Disability Benefits.

Carolyn S Dewa1, Jeffrey S Hoch, Paula Goering.   

Abstract

This study explored the effects of out-of-pocket expenditures on antidepressant use among workers receiving depression-related short-term disability benefits. The authors examine the association between workers' out-of-pocket expenditures prior to their disability episode and their use, or delay in use, of antidepressants during the episode. The results indicate that higher out-of-pocket expenditures for antidepressants prior to the disability episode were associated with higher odds of using an antidepressant during the episode. However, results also suggested that higher out-of-pocket expenditures for other prescriptions were associated with significantly lower odds of an antidepressant claim during the episode. Greater prior out-of-pocket expenditures for other prescription drugs may serve as a barrier to accessing antidepressant treatment. Workers receiving short-term disability benefits who have previously purchased prescriptions for other conditions may be more sensitive to out-of-pocket expenditures for antidepressant prescriptions.
Copyright © 2008 Longwoods Publishing.

Entities:  

Year:  2008        PMID: 19377363      PMCID: PMC2645219     

Source DB:  PubMed          Journal:  Healthc Policy        ISSN: 1715-6572


  24 in total

1.  A chronic disease score from automated pharmacy data.

Authors:  M Von Korff; E H Wagner; K Saunders
Journal:  J Clin Epidemiol       Date:  1992-02       Impact factor: 6.437

Review 2.  The use of claims databases for outcomes research: rationale, challenges, and strategies.

Authors:  B R Motheral; K A Fairman
Journal:  Clin Ther       Date:  1997 Mar-Apr       Impact factor: 3.393

3.  The demand for prescription drugs as a function of cost-sharing.

Authors:  A Leibowitz; W G Manning; J P Newhouse
Journal:  Soc Sci Med       Date:  1985       Impact factor: 4.634

4.  Workplace performance effects from chronic depression and its treatment.

Authors:  E R Berndt; S N Finkelstein; P E Greenberg; R H Howland; A Keith; A J Rush; J Russell; M B Keller
Journal:  J Health Econ       Date:  1998-10       Impact factor: 3.883

5.  Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey.

Authors:  R C Kessler; C B Nelson; K A McGonagle; J Liu; M Swartz; D G Blazer
Journal:  Br J Psychiatry Suppl       Date:  1996-06

6.  National trends in the use of psychotropic medications by children.

Authors:  Mark Olfson; Steven C Marcus; Myrna M Weissman; Peter S Jensen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-05       Impact factor: 8.829

7.  One-year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age.

Authors:  D R Offord; M H Boyle; D Campbell; P Goering; E Lin; M Wong; Y A Racine
Journal:  Can J Psychiatry       Date:  1996-11       Impact factor: 4.356

8.  Depression-related short-term disability in an employed population.

Authors:  Carolyn S Dewa; Paula Goering; Elizabeth Lin; Michael Paterson
Journal:  J Occup Environ Med       Date:  2002-07       Impact factor: 2.162

9.  Pharmacy benefits and the use of drugs by the chronically ill.

Authors:  Dana P Goldman; Geoffrey F Joyce; Jose J Escarce; Jennifer E Pace; Matthew D Solomon; Marianne Laouri; Pamela B Landsman; Steven M Teutsch
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

10.  Patterns of antidepressant use in community practice.

Authors:  G E Simon; M VonKorff; E H Wagner; W Barlow
Journal:  Gen Hosp Psychiatry       Date:  1993-11       Impact factor: 3.238

View more
  1 in total

1.  Impact of regional copayment policy on selective serotonin reuptake inhibitor (SSRI) consumption and expenditure in Italy.

Authors:  Gianfranco Damiani; Bruno Federico; Giulia Silvestrini; Caterina Bianca Neve Aurora Bianchi; Angela Anselmi; Lanfranco Iodice; Alessandra Ronconi; Pierluigi Navarra; Roberto Da Cas; Roberto Raschetti; Walter Ricciardi
Journal:  Eur J Clin Pharmacol       Date:  2012-10-23       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.